Novo Nordisk (NVO) reported Q3 net sales of 79.20 billion Danish kroner ($8.59 billion), compared with 74.98 billion kroner a year earlier.
Analysts polled by FactSet expected 73.90 billion kroner.
The company said it now expects 2026 adjusted sales of between -2% and 2% at constant exchange rates, compared with a 0% to 6% decline previously, driven by increased expectations for GLP-1 product sales.
Analysts surveyed by FactSet expected 302.75 billion kroner.
Separately, Novo Nordisk said its CFO, Karsten Munk Knudsen, will leave the company and Luigi La Corte will take over the role, according to a Reuters report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments